495 related articles for article (PubMed ID: 14564313)
21. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
[TBL] [Abstract][Full Text] [Related]
22. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy.
Arampatzis CA; Goedhart D; Serruys PW; Saia F; Lemos PA; de Feyter P;
Am Heart J; 2005 Feb; 149(2):329-35. PubMed ID: 15846273
[TBL] [Abstract][Full Text] [Related]
23. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
Reckless JP; Henry P; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO; Lis K; Brudi P; Allen C
Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852
[TBL] [Abstract][Full Text] [Related]
24. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors.
Naslafkih A; Sestier F
J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915
[TBL] [Abstract][Full Text] [Related]
25. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
26. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
27. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
Saito Y; Yokoyama M; Origasa H; Matsuzaki M; Matsuzawa Y; Ishikawa Y; Oikawa S; Sasaki J; Hishida H; Itakura H; Kita T; Kitabatake A; Nakaya N; Sakata T; Shimada K; Shirato K;
Atherosclerosis; 2008 Sep; 200(1):135-40. PubMed ID: 18667204
[TBL] [Abstract][Full Text] [Related]
28. Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics.
Ong HT; Cheah JS
Chin Med J (Engl); 2008 Aug; 121(16):1588-94. PubMed ID: 18982874
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study.
Willich SN; Müller-Nordhorn J; Sonntag F; Völler H; Meyer-Sabellek W; Wegscheider K; Windler E; Katus H
Am Heart J; 2004 Dec; 148(6):1060-7. PubMed ID: 15632894
[TBL] [Abstract][Full Text] [Related]
31. [Results of clinical epidemiology and intervention trial of hyperlipidemia in Japan].
Itakura H
Nihon Rinsho; 2002 May; 60(5):889-98. PubMed ID: 12029990
[TBL] [Abstract][Full Text] [Related]
32. Hypercholesterolemia. The evidence supports use of statins.
Aronow WS
Geriatrics; 2003 Aug; 58(8):18-20, 26-8, 31-2. PubMed ID: 12938249
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
[TBL] [Abstract][Full Text] [Related]
34. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
35. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
[TBL] [Abstract][Full Text] [Related]
36. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
37. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Sampalis JS; Bissonnette S; Habib R; Boukas S;
Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
[TBL] [Abstract][Full Text] [Related]
38. Reduction of myocardial ischemia with simvastatin in addition to conventional treatment in patients with chronic coronary artery disease.
Verri V; Cunha AB; Tessarolo LE; Carneiro RC; Romêo Filho LJ
Rev Port Cardiol; 2004 Sep; 23(9):1089-105. PubMed ID: 15587571
[TBL] [Abstract][Full Text] [Related]
39. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
Hueb W; Lopes NH; Gersh BJ; Soares P; Machado LA; Jatene FB; Oliveira SA; Ramires JA
Circulation; 2007 Mar; 115(9):1082-9. PubMed ID: 17339566
[TBL] [Abstract][Full Text] [Related]
40. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
Zhao SP; Peng DQ; Yu BL; Huo Y;
Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
